|Related Categories||Androgen Modulators, Antitumor Agents, Bioactive Small Molecules, Cancer Research, Cell Biology,|
human ... GNRHR(2798)|
rat ... Gnrhr(81668)
Luteinizing hormone releasing hormone (LH-RH) agonist.
Gonadotropin-releasing hormone agonist has the ability to induce increased matrix metalloproteinase (MMP)-2 and membrane type 1-MMP expression in corpora lutea, and structural luteolysis in rats. Goto, T., et al. J. Endocrinol. 161, 393-402, (1999)
Spontaneous reports of seizure in association with leuprolide (lupron depot), goserelin (zoladex implant), and naferelin (synarel nasal spray). Gatti J, Brinker A, and Avigan M Obstet. Gynecol. 121(5), 1107, (2013)
Dehydroepiandrosterone sulfate levels reflect endogenous luteinizing hormone production and response to human chorionic gonadotropin challenge in older female macaque (Macaca fascicularis). Moran FM, Chen J, Gee NA, et al. Menopause 20(3), 329-35, (2013)
Leuprorelin acetate long-lasting effects on GnRH receptors of prostate cancer cells: an atomic force microscopy study of agonist/receptor interaction. Lama G, Papi M, Angelucci C, et al. PLoS ONE 8(1), e52530, (2013)
Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis: a retrospective study. Morelli M, Rocca ML, Venturella R, et al. Gynecol. Endocrinol. 29(4), 305-8, (2013)
Treatment of urinary retention caused by uterine leiomyoma with a gonadotropin-releasing hormone agonist: case report and review. Chu CM, Dabney L, and Hardart A Female Pelvic Med. Reconstr. Surg. 19(1), 52-5, (2013)
Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients. Aydiner A, Kilic L, Yildiz I, et al. Med. Oncol. 30(1), 354, (2013)
A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Amato R, Stepankiw M, and Gonzales P Cancer Chemother. Pharmacol. 71(6), 1629-34, (2013)
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Corn PG, Song DY, Heath E, et al. Int. J. Radiat. Oncol. Biol. Phys. 86(3), 540-5, (2013)
Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer. van der Sluis TM, van Moorselaar RJ, Meuleman EJ, et al. Urology 81(5), 1005-9, (2013)
Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study. Baller EB, Wei SM, Kohn PD, et al. Am. J. Psychiatry 170(3), 305-14, (2013)
Independent effects of testosterone on lipid oxidation and VLDL-TG production: a randomized, double-blind, placebo-controlled, crossover study. Høst C, Gormsen LC, Christensen B, et al. Diabetes 62(5), 1409-16, (2013)
Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists. Takashi Imada et al J. Med. Chem. 49, 3809-25, (2006)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?